Verified factor-similar pair

QVMS vs SPSM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
92
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • QVMS has the higher backtested relative Sharpe (1.218 vs 1.027).
  • SPSM has the lower published fee (0.03% vs 0.15%).
  • SPSM is cheaper on dividend valuation (117 vs 131, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

QVMS

Invesco S&P SmallCap 600 QVM Multi-factor ETF
SMB
Adj. R2
0.974
Rel. Sharpe
1.218
Mkt beta
0.98
AUM
US$217M
MER
0.15%
Valuation
131

SPSM

State Street SPDR Portfolio S&P 600 Small Cap ETF
SMB
Adj. R2
0.978
Rel. Sharpe
1.027
Mkt beta
0.98
AUM
US$14.7B
MER
0.03%
Valuation
117

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
QVMS
+1.00
|t|
+20.2
SPSM
+0.91
|t|
+31.2
diff +0.10
HML
QVMS
+0.23
|t|
+4.4
SPSM
+0.19
|t|
+6.7
diff +0.05
RMW
QVMS
+0.19
|t|
+4.2
SPSM
+0.08
|t|
+2.4
diff +0.11
CMA
QVMS
+0.01
|t|
+0.1
SPSM
+0.01
|t|
+0.3
diff -0.00
UMD
QVMS
+0.07
|t|
+2.1
SPSM
+0.07
|t|
+3.5
diff +0.00

Why This Pair Matches

Exposure level
91
Exposure shape
100
Mkt beta diff
0.01
Rel. Sharpe diff
0.192

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

QVMS fund page SPSM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.